✕
For Patients & Families
Our Science
About Us
Connect with Us
September 2025: European Academy of Dermatology and Venereology Congress
Demonstration of Early Proof-of-Concept for STAR-0310, a Long-Acting OX40 Receptor Antagonist: Initial Safety, PK, and PD Results from a Phase 1a Trial
July 2025: US Hereditary Angioedema Association National Summit
ALPHA-ORBIT – a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Participants with Hereditary Angioedema (HAE)
July 2025: US Hereditary Angioedema Association National Summit
Long-Term Safety and Efficacy of Navenibart in Participants with Hereditary Angioedema (HAE): Initial Combined Results from ALPHA-STAR and ALPHA-SOLAR
July 2025: US Hereditary Angioedema Association National Summit
Recruitment Challenges for Rare Disease Clinical Trials: A Systematic Review
July 2025: US Hereditary Angioedema Association National Summit
Treatment with Navenibart (STAR-0215) Reduces Attack Severity and Use of Rescue Medication in Patients with Hereditary Angioedema (HAE): Interim Results from the ALPHA-STAR Trial
June 2025: European Academy of Allergy and Clinical Immunology Annual Congress
Long-term Safety and Efficacy of Navenibart in Participants with Hereditary Angioedema (HAE): Initial Combined Results from ALPHA-STAR and ALPHA-SOLAR
June 2025: European Academy of Allergy and Clinical Immunology Annual Congress
Unveiling the Underlying Mechanism of Differentiation for STAR-0310, an Anti-OX40 Antibody for Atopic Dermatitis
June 2025: European Academy of Allergy and Clinical Immunology Annual Congress
Results from the ALPHA-STAR Trial, a Phase 1b/2 Single and Multiple Dose Study to Assess the Safety, Tolerability, Clinical Activity, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Navenibart in Participants with Hereditary Angioedema (HAE)
June 2025: European Academy of Allergy and Clinical Immunology Annual Congress
ALPHA-ORBIT: a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Participants with Hereditary Angioedema (HAE)
May 2025: Eastern Allergy Conference
Treatment with Navenibart (STAR-0215) Reduces Attack Severity and Use of Rescue Medication in Patients with Hereditary Angioedema (HAE): Interim Results from the ALPHA-STAR Trial
